There has been a lot of discussion of the Independent Payments Advisory Board (IPAB) lately, including pretty heated testimony at the House of Representative Energy & Commerce committee in the last few days.
IPAB is the primary vehicle whereby the Paient Protection and Affordable Care Act (PPACA) will deny new medicines to Medicare beneficaries, in a futile attempt to contain costs.
The Washington Times ran my column on IPAB. Read the entire article here.
Research and commentary from a former senior executive in the U.S. Department of Health & Human Services
No comments:
Post a Comment